# Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-21a40f6e
Ticker: STTK
Company: Shattuck Labs
Source: Shattuck Labs
Published: 2025-12-15 21:15 EST
## Summary

AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage...

## Article Body
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer.

The inducement awards consist of non-qualified stock options to purchase 206,000 shares of Shattuck’s common stock with an exercise price of $3.23 per share. The stock options have a maximum term of 10 years. A total of 25% of the award will vest on November 17, 2026, with the remainder vesting in equal monthly installments over the subsequent 36 months. The stock options were granted as a material inducement to the individual’s employment and were approved by Shattuck’s independent Compensation Committee, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted outside of the Company’s 2020 Equity Incentive Plan, but are generally subject to the same terms and conditions that apply to awards granted under such plan.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:

Andrew R. Neill Chief Financial Officer Shattuck Labs, Inc. InvestorRelations@shattucklabs.com
## Recent Company News
- 2026-06-10 04:21 EST — [Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04) — Source: Shattuck Labs
- 2026-06-09 20:18 EST — [Shattuck Labs, Inc. Announces Proposed Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1) — Source: Shattuck Labs
- 2026-06-09 12:00 EST — [Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16) — Source: Shattuck Labs
- 2026-06-08 10:00 EST — [Shattuck Labs Announces Phase 1 Results for SL-325](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-phase-1-results-for-sl-325-e7f7caf7) — Source: Shattuck Labs
- 2026-06-05 20:05 EST — [Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8](https://biopharmsignal.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-phase-1-clinical-data-of-sl-3-d25fd1ba) — Source: Shattuck Labs
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)